Journals / Türk Biyokimya Dergisi / 2019 / Cilt: 44 - Sayı: 4

Diagnostic performance of microRNAs in the circulation in differential diagnosis of BPH, chronic prostatitis and prostate cancer

BPH, kronik prostatit ve prostat kanserinin ayrıcı tanısında dolaşımdaki mikroRNA’ların tanısal performansı

Pages
417–425
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, a higher specificity and sensitivity were obtained in distin- guishing BPH and PCa when data for diagnostic potential of miRNAs were analyzed without including chronic pro- static group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: In this study, the objective was to evalu- ate the diagnostic performance of some miRNAs, which were shown to have a diagnostic value for prostate cancer (PCa), and the effect of chronic prostatitis in distinguish- ing benign prostatic hyperplasia (BPH) and PCa.Materials and methods: Serum levels of 11 miRNAs were investigated in BPH, chronic prostatitis and PCa patients.
📊
Key Findings & Data:Measurements were performed using qRT-PCR.Results: In the analysis, serum levels of miR-375, -125b- 5p, -30c-5p, -26b-5p, and let-7c-5p were downregulated in cancer compared with non-cancer group and AUCs of these miRNAs in distinguishing PCa group from non-can- cer group were calculated as 0.781, 0.782, 0.762, 0.874, and 0.845, respectively.
💡
Conclusion & Impact:Furthermore, a higher specificity and sensitivity were obtained in distin- guishing BPH and PCa when data for diagnostic potential of miRNAs were analyzed without including chronic pro- static group.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: In this study, the objective was to evalu- ate the diagnostic performance of some miRNAs, which were shown to have a diagnostic value for prostate cancer (PCa), and the effect of chronic prostatitis in distinguish- ing benign prostatic hyperplasia (BPH) and PCa.Materials and methods: Serum levels of 11 miRNAs were investigated in BPH, chronic prostatitis and PCa patients. Measurements were performed using qRT-PCR.Results: In the analysis, serum levels of miR-375, -125b- 5p, -30c-5p, -26b-5p, and let-7c-5p were downregulated in cancer compared with non-cancer group and AUCs of these miRNAs in distinguishing PCa group from non-can- cer group were calculated as 0.781, 0.782, 0.762, 0.874, and 0.845, respectively. AUC of the combination of miR-375 and miR-26b-5p in distinguishing PCa group from non-cancer group was 0.891, AUC of these two miRNAs in distinguish- ing PCa group from BPH group was 0.944.Conclusion: In our study, 11 miRNAs were studied and 5 of these miRNAs were considered as biomarker candidates as these miRNAs, individually or combined, could be used to distinguish PCa from benign conditions. Furthermore, a higher specificity and sensitivity were obtained in distin- guishing BPH and PCa when data for diagnostic potential of miRNAs were analyzed without including chronic pro- static group.

Özet

Amaç: Bu çalışma ile prostat kanserinde tanısal değeri olduğuna yönelik bilimsel literatürde çalışmalar bulunan bazı miRNA’ların prostat kanseri tanısındaki performansı- nın ve kronik prostatitin, BPH ve prostat kanseri (PK) ayrı- mına etkisinin değerlendirmesi amaçlanmıştır. Gereç ve Yöntem: Çalışma kapsamında toplam 11 miR- NA’nın BPH’lı, kronik prostatitli ve prostat kanserli hasta serumlarındaki seviyeleri değerlendirilmiştir. Ölçümler, qRT-PCR kullanılarak gerçekleştirilmiştir. Bulgular: Yapılan analizde, kanser olmayan gruba kıyasla kanser grubunda miR-375, -125b-5p, -30c-5p, -26b-5p ve let- 7c-5p serum seviyelerinin downregüle olduğu görülmüş ve bu miRNA’ların kanser olmayan gruptan PK’nın ayrımın- daki AUC’leri sırasıyla; 0.781, 0.782, 0.762, 0.874 ve 0.845 olarak hesaplanmıştır. miR-375 ve miR-26b-5p kombinas- yonunu için kanser olmayan hasta grubundan kanser gru- bunun ayırımında AUC 0.891, BPH’tan kanser grubunun ayrımında AUC 0.944 olarak hesaplanmıştır. TartışmaveSonuç:Çalışmamızdadüzeyleri ölçülen 11 miRNA’nın 5’nin, PK’nın benign durumlardan ayrı- mında tek tek ya da kombine olarak güçlü birer biyobe- lirteç adayı olabilecekleri değerlendirilmiştir. Ayrıca çalışmamızda analiz edilen miRNA’ların tanısal yeterli- liğine ilişkin bulgular değerlendirildiğinde, kronik pros- tatit grubunun analize dahil edilmemesi ile BPH ve PK ayrımında daha yüksek spesifisite ve sensitivite değerleri elde edilmiştir.

🔖

Cite This Article

EROĞLU, O., DÜLGEROĞLU, Y. (2022). Diagnostic performance of microRNAs in the circulation in differential diagnosis of BPH, chronic prostatitis and prostate cancer. Türk Biyokimya Dergisi, Cilt: 44 - Sayı: 4, 417–425. https://ajindex.com/articles/620823

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. GLOBOCAN. “Prostate Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012”, International Agency for Research on Cancer, http://globocan.iarc.fr/old/FactSheets/ cancers/prostate-new.asp. Accessed: 3 Aug 2018
  2. Bailey SV, Brewster SF. Prostate cancer: to screen or not to screen. Arch Esp Urol 2011;64:406–18
  3. Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 2017;4:148–51
  4. Peng Y, Croce CM. The role of microRNAs in human cancer. Sig- nal Transduct Target Ther 2016;1:15004
  5. Vanacore D, Boccellino M, Rossetti S, Cavaliere C, D’Aniello C, Di Franco R. Micrornas in prostate cancer: an overview. Oncotarget 2017;8:50240–51
  6. Markopoulos GS, Roupakia E, Tokamani M, Alabasi G, Sandalt- zopoulos R, Marcu KB, et al. Roles of NF-кB signaling in the regulation of miRNAs impacting on inflammation in cancer. Biomedicines 2018;6:E40
  7. Cheng I, Witte JS, Jacobsen SJ, Haque R, Quinn VP, Quesenberry CP. Prostatitis, sexually transmitted diseases, and prostate can- cer: the California Men’s Health Study. PLoS One 2010;5:e8736
  8. Kiechle FL, Betsou F, Blakeney J, Calam RR, Catalasan IM, Raj P, et al. Procedures for the handling and processing of blood speci- mens for common laboratory tests; Approved Guideline, Fourth Edition. CLSI Document 2010;30:H18–A4
  9. Mihelich BL, Maranville JC, Nolley R, Peehl DM, Nonn L. Elevated serum microRNA levels associate with absence of high-grade pros- tate cancer in a retrospective cohort. PLoS One 2015;10:e0124245
  10. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the serum of prostate cancer patients. Cancer Res 2011;71:550–60
  11. Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, et al. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget 2014;5:824–40
  12. Akbayır S, Muslu N, Erden S, Bozlu M. Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL. Turk J Urol 2016;42:247–55
  13. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova- Agadjanyan EL, et al. Circulating microRNAs as stable blood- based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513–8
  14. Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, et al. Discovery of circulating microRNAs associated with human prostate cancer usi